Illumina Inc., a global leader in DNA sequencing and array-based technologies, announced the launch of DRAGEN™ v4.3, the latest version of its DRAGEN™ software, part of the Illumina Connected Software portfolio, for analysis of next-generation sequencing data.
Latest version includes a prebuilt pangenome capturing more genetic diversity, reducing ancestry bias, and improving accuracy
SAN DIEGO, June 11, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of DRAGEN™ v4.3, the latest version of its DRAGEN™ software, part of the Illumina Connected Software portfolio, for analysis of next-generation sequencing data.
“We are excited to launch DRAGEN v4.3, with significant enhancements and additions to our analysis tools, empowering researchers and geneticists to maximize the value of the genome,” said Rami Mehio, head of Software & Informatics at Illumina. “DRAGEN v4.3 includes our next-generation and most accurate multigenome mapping technology, built-in mosaic calling, advancements in machine learning, and the ability to genotype difficult genes to unlock deeper insights into the human genome with greater power, accuracy, and efficiency.”
DRAGEN’s innovation in multigenome mapping complements the efforts led by the Human Pangenome Reference Consortium (HPRC). The HPRC, funded by the National Human Genome Research Institute, aims to equip the genomics community with high-quality assemblies from diverse ancestries and combine them into a reference human pangenome.
“We have already delivered 47 high-quality assemblies that are now used by researchers around the globe,” said Karen Miga, PhD, director of the Reference Production Center at the HPRC and assistant professor, Biomolecular Engineering, University of California, Santa Cruz. “With DRAGEN v4.3, and through the cloud apps, a DRAGEN customer can now leverage all or a subset of the 47 HPRC samples, allowing the user to select the ancestries of choice to power their DRAGEN multigenome mapping.”
Benedict Paten, PhD, co-lead of the HPRC and associate professor, Biomolecular Engineering, University of California, Santa Cruz, added, “The accuracy improvement over traditional mapping is substantial and is expected to continue to improve when additional assemblies are incorporated in the pangenome.”
DRAGEN v4.3 features a host of industry-leading innovations that together enable a more comprehensive genome, including:
- Next-generation multigenome with 128 samples—DRAGEN’s multigenome reference mapping now harnesses the power of a prebuilt pangenome derived from 128 samples across 26 ancestries, capturing more genetic diversity, reducing ancestry bias, and improving accuracy. Customers can build custom DRAGEN multigenome references on the Illumina cloud.
- Machine learning mosaic model—A new feature in the small variant caller enables mosaic variant calling for low allele frequency variants, enhancing precision in translational and research settings.
- A new family of specialized callers, with novel variant discovery capability like multiregion joint detection. These callers enable comprehensive genotyping of difficult genes in segmental duplication regions, such as PMS2 for hereditary cancer; SMN1, SMN2, STRC, and NEB for carrier screening; and TTN and IKBKG for newborn screening.
- AI-powered annotations—DRAGEN v4.3 features an updated annotation engine, Connected Annotations, which leverages SpliceAI, a state-of-the-art splicing prediction algorithm, and PrimateAI-3D, a deep-learning network trained on millions of common genetic variants from over 200 primate species that reduces variants of unknown significance.
- Other advancements include RNA accuracy improvements and the extension of lossless ORA compression functionality, which can now support human methylation data and nonhuman data with a high compression ratio.
Broad Clinical Labs has been systematically researching the accuracy of variant calls made by DRAGEN v4.3. Marina DiStefano, PhD, FACMG, associate lab director at Broad Clinical Labs, said: “We generated whole-genome sequence data from samples with confirmed calls in genes covered by DRAGEN v4.3 specialized callers, such as PMS2, NEB, and HBA, and from samples with orthogonally confirmed CNV calls. We also analyzed very-high-coverage WGS samples for mosaic evaluation. We are happy with the accuracy and speed and believe that DRAGEN v4.3 is a powerful tool for our clinical whole-genome research.”
Visit the DRAGEN page to learn more.
About DRAGEN
Illumina DRAGEN is a leading secondary analysis software in the genomics market, and its continuous innovations have set new standards for accuracy, comprehensiveness, and efficiency. DRAGEN analysis leads in accuracy for germline and somatic variant calling demonstrated in industry challenges from PrecisionFDA. With availability across multiple deployment options, from a standalone server to Illumina cloud solutions and on board select sequencers, DRAGEN streamlines sequencing data acquisition and analysis.
Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing, manufacturing, and launching new products and services; (ii) customer uptake of, and satisfaction with, new products and services; and (iii) legislative, regulatory and economic developments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Salli Schwartz
858-291-6421
IR@illumina.com
Media:
Samantha Beal
PR@illumina.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-dragen-v4-3-powers-most-comprehensive-accurate-genome-with-industry-leading-innovations-302169191.html
SOURCE Illumina, Inc.
Company Codes: NASDAQ-NMS:ILMN
